Publikationen (96) Publikationen von MARÍA GALINDO IZQUIERDO

2024

  1. Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist's judgement?

    Rheumatology (Oxford, England), Vol. 63, Núm. 1, pp. 72-78

2023

  1. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

  2. Gender biases in Spanish rheumatology: Perception and facts

    Reumatologia Clinica, Vol. 19, Núm. 7, pp. 392-401

  3. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs

    Rheumatology and Therapy, Vol. 10, Núm. 2, pp. 357-373

  4. Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 61

  5. Searching for a prognostic index in lupus nephritis

    European journal of medical research, Vol. 28, Núm. 1, pp. 19

  6. mTOR inhibitors in a patient with lupus nephritis; why not?

    Nefrologia

  7. mTOR inhibitors in a patient with lupus nephritis; why not?

    Nefrologia

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study

    Rheumatology (Oxford, England), Vol. 62, Núm. 1, pp. 217-224

  3. Importance of family planning in patients with immune-mediated inflammatory diseases: a multidisciplinary approach

    Reumatologia Clinica, Vol. 18, Núm. 4, pp. 200-206

  4. SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection

    Annals of the Rheumatic Diseases, Vol. 81, Núm. 9, pp. 1337-1338

  5. Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines

    European Journal of Internal Medicine, Vol. 99, pp. 19-21

2021

  1. Complement as a Therapeutic Target in Systemic Autoimmune Diseases

    Cells, Vol. 10, Núm. 1

  2. Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain

    Reumatologia Clinica, Vol. 17, Núm. 5, pp. 245-249

  3. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563

  4. Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER)

    Rheumatology (Oxford, England), Vol. 60, Núm. 4, pp. 1793-1803

  5. Pregnancy Control in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Part 1: Infertility, Ovarian Preservation and Preconception Assessment. Consensus Document of the Spanish Society of Gynaecology and Obstetrics (SEGO), the Spanish Society of Internal Medicine (SEMI) and the Spanish Society of Rheumatology (SER)

    Reumatologia Clinica, Vol. 17, Núm. 2, pp. 61-66

  6. Pregnancy control in Patients with Systemic Lupus Erythematosus/Antiphospholipid Syndrome. Part 3: Childbirth. Puerperium. Breastfeeding Contraception. Newborn

    Reumatologia Clinica, Vol. 17, Núm. 4, pp. 183-186

  7. Pregnancy control in patients with systemic lupus erythematosus/antiphospholipid syndrome. Part 2: Pregnancy follow-up

    Reumatologia Clinica, Vol. 17, Núm. 3, pp. 125-131